Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Panot Sainamthip"'
1
Akademický článek
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls
Autor: Nussara Pakvisal, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Nassamon Wanlapakorn, Ritthideach Yorsaeng, Yong Poovorawan, Piyapoom Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Suebpong Tanasanvimon, Passakorn Wanchaijiraboon
Publikováno v: Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overal
Externí odkaz: https://doaj.org/article/1a3266a837cc424ba86d3a059ad64f26
Zobrazit plný text záznamu
3
Akademický článek
The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial
Autor: Panot Sainamthip, Siriwimon Saichaemchan, Bancha Satirapoj, Naiyarat Prasongsook
Publikováno v: JCO Global Oncology, Vol , Iss 8 (2022)
PURPOSENephrotoxicity is a major dose-limiting toxicity among patients with cancer who were treated with cisplatin. Although no standard approach is available to prevent cisplatin-induced nephrotoxicity, administering intravenous isotonic saline is r
Externí odkaz: https://doaj.org/article/7dca92994a0e43299e7f52a0aca6d66e
Zobrazit plný text záznamu
4
Akademický článek
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
Autor: Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal
Publikováno v: Vaccines, Vol 11, Iss 2, p 356 (2023)
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who
Externí odkaz: https://doaj.org/article/7b609b8e83ae4e269804e0645aba8b73
Zobrazit plný text záznamu
5
Akademický článek
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
Autor: Passakorn Wanchaijiraboon, Nattaya Teeyapun, Nussara Pakvisal, Panot Sainamthip, Thiti Susiriwatananont, Nicha Zungsontiporn, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Worata Klinsawat, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Yong Poovorawan, Sutima Luangdilok
Publikováno v: Vaccines, Vol 10, Iss 10, p 1662 (2022)
There are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up
Externí odkaz: https://doaj.org/article/bcf02b0081da41388d16e97573166523
Zobrazit plný text záznamu
6
Akademický článek
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
Autor: Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon
Publikováno v: Vaccines, Vol 10, Iss 10, p 1613 (2022)
No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with the heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during the shortage of vaccine supply are available. Forty-four cancer pati
Externí odkaz: https://doaj.org/article/722c3fd50b834e08ac91576fd2d6c969
Zobrazit plný text záznamu
8
Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study
Autor: Sakkarin Chirapongsathorn, Naiyarat Prasongsook, Chutcharn Kongphanich, Panot Sainamthip
Publikováno v: World Journal of Clinical Cases
BACKGROUND Even in the immuno-oncology era, transcatheter arterial chemoembolisation (TACE) is the most effective way to treat intermediate stage hepatocellular carcinoma (HCC). Postembolisation syndrome (PES) is the most common side effect from TACE
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::474e5e175ae741135d042735db309c96
http://europepmc.org/articles/PMC8567509
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje